サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1586371

肺炎球菌ワクチン市場、規模、シェア、動向、産業分析レポート：ワクチンタイプ別、製品タイプ別、エンドユーザー別、地域別、セグメント別予測、2024年～2032年

Pneumococcal Vaccine Market Size, Share, Trends, Industry Analysis Report, By Vaccine Type (Pneumococcal Conjugate Vaccine, and Pneumococcal Polysaccharide Vaccine); By Product Type; By End User; By Region; Segment Forecast, 2024 - 2032

出版日
ページ情報
英文 118 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
肺炎球菌ワクチン市場、規模、シェア、動向、産業分析レポート：ワクチンタイプ別、製品タイプ別、エンドユーザー別、地域別、セグメント別予測、2024年～2032年
出版日: 2024年10月01日
発行: Polaris Market Research
ページ情報: 英文 118 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、世界の肺炎球菌ワクチンの市場規模は2032年までに144億3,000万米ドルに達する見込みです。このレポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

肺炎球菌ワクチン市場は、肺炎球菌感染症に対する意識の高まりと、政府が後援する予防接種プログラムの拡大により大きな成長を遂げています。公衆衛生キャンペーンが肺炎や髄膜炎を含む肺炎球菌性疾患の危険性を強調するにつれ、個人やヘルスケア提供者はワクチン接種を求める傾向が強くなっています。さらに、世界各国の政府は、地域社会の健康増進と肺炎球菌感染症に関連するヘルスケア費用の削減を目的とした強力な予防接種イニシアチブを実施しています。このようなプログラムには助成金や教育資源が含まれていることが多く、十分なサービスを受けていない人々にとってワクチンがより身近なものとなっています。意識が高まり続け、予防接種への取り組みが強化されるにつれ、肺炎球菌ワクチンの需要は大幅に増加し、肺炎球菌ワクチン市場の成長にプラスの影響を与えると予想されます。

肺炎球菌ワクチン市場は、ワクチン接種を広く推進する政府の取り組みや保健政策によって牽引されています。これらのプログラムは、肺炎や髄膜炎などの肺炎球菌性疾患の発生率を減少させることにより、公衆衛生を向上させることを目的としています。政府が資金援助や啓発キャンペーンを含む包括的な予防接種戦略を実施するにつれ、ワクチンへのアクセスが改善し、ワクチン接種率の向上につながります。

より効果的な肺炎球菌結合型ワクチン（PCV）の開発を目的としたバイオテクノロジー企業と市場企業のパートナーシップ開拓の増加は、予測数年間における肺炎球菌ワクチン市場の成長に拍車をかけています。例えば、2023年6月、SKバイオサイエンスはサノフィと共同で21価のPCVであるGBP410を開発し、幼児と乳児を対象とした第2相試験で良好な結果を示しました。同様に、2024年3月には、ファイザーの20価のPCVであるPREVENAR 20が、欧州委員会から欧州全域および全世界の乳幼児、小児、青少年に対する予防接種の承認を取得しました。このような戦略的提携は、研究能力の強化、市場開拓の迅速化、ワクチンアクセスの拡大をもたらし、最終的に予測される数年間の市場成長を促進します。

肺炎球菌ワクチン市場レポートハイライト

肺炎球菌多糖体ワクチン（PPV）セグメントは、主に世界的に受け入れられ、入手が容易であることから、2023年に最大の市場シェアを占めました。

肺炎球菌結合型ワクチン（PCV）セグメントは、PCVが肺炎球菌をより広範囲にカバーしていることから、調査期間中に最も高い成長が見込まれます。

プレブナー13は、幅広い年齢層に対応し、より効率的な治療が可能であることから、2023年に最大の市場シェアを占めました。

肺炎球菌ワクチン開発への投資が増加していることから、アジア太平洋地域が調査期間中に最も速い成長を記録すると予測されています。

グローバル企業は、GSK plc、Pfizer Inc、Merck、Serum Institute、CSL Ltd.、Sanofiです。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の肺炎球菌ワクチン市場の洞察

  • 市場スナップショット
  • 肺炎球菌ワクチン市場力学
    • 促進要因と機会
      • あらゆる年齢層における肺炎球菌感染症の発生率上昇が市場の成長を牽引
      • ワクチン接種の普及を促進する保健政策が市場規模を押し上げている
    • 抑制要因と課題
      • 規制上のハードル
  • PESTEL分析
  • 肺炎球菌ワクチン市場の動向
  • バリューチェーン分析
  • COVID-19の影響分析

第5章 世界の肺炎球菌ワクチン市場：ワクチタイプ別

  • 主な調査結果
  • イントロダクション
  • 肺炎球菌結合ワクチン
  • 肺炎球菌多糖体ワクチン

第6章 世界の肺炎球菌ワクチン市場：製品別

  • 主な調査結果
  • イントロダクション
  • プレベナー13
  • シンフロリックス
  • ニューモバックス23
  • その他の製品

第7章 世界の肺炎球菌ワクチン市場：エンドユーザー別

  • 主な調査結果
  • イントロダクション
  • 公共部門
  • 民間セクター

第8章 世界の肺炎球菌ワクチン市場：地域別

  • 主な調査結果
  • イントロダクション
    • 肺炎球菌ワクチン市場評価：地域、2019年～2032年
  • 北米
    • 北米：ワクチンタイプ別、2019年～2032年
    • 北米：製品別、2019年～2032年
    • 北米：エンドユーザー別、2019～2032年
    • 米国
    • カナダ
  • 欧州
    • 欧州：ワクチンタイプ別、2019年～2032年
    • 欧州：製品別、2019年～2032年
    • 欧州：エンドユーザー別、2019年～2032年
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • オランダ
    • ロシア
    • その他欧州
  • アジア太平洋
    • アジア太平洋地域：ワクチンタイプ別、2019年～2032年
    • アジア太平洋地域：製品別、2019年～2032年
    • アジア太平洋地域：エンドユーザー別、2019年～2032年
    • 中国
    • インド
    • マレーシア
    • 日本
    • インドネシア
    • 韓国
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ
    • 中東・アフリカ：ワクチンタイプ別、2019年～2032年
    • 中東・アフリカ：製品別、2019年～2032年
    • 中東およびアフリカ：エンドユーザー別、2019年～2032年
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東・アフリカ
  • ラテンアメリカ
    • ラテンアメリカ：ワクチンタイプ別、2019年～2032年
    • ラテンアメリカ：製品別、2019年～2032年
    • ラテンアメリカ：エンドユーザー別、2019年～2032年
    • メキシコ
    • ブラジル
    • アルゼンチン
    • その他ラテンアメリカ

第9章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第10章 企業プロファイル

  • GSK plc
  • Pfizer Inc.
  • Merck KGaA
  • Serum Institute of India Pvt. Ltd.
  • CSL Ltd.
  • Sanofi S.A
  • Walvax Biotechnology Co., Ltd.
  • Beijing Minhai Biotechnology Co., Ltd
  • Johnson & Johnson
  • AstraZeneca
  • Novavax
図表

List of Tables:

  • Table 1 Global Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 2 Global Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 3 Global Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 4 North America: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 5 North America: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 6 North America: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 7 U.S.: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 8 U.S.: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 9 U.S.: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 10 Canada: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 11 Canada: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 12 Canada: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 13 Europe: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 14 Europe: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 15 Europe: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 16 UK: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 17 UK: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 18 UK: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 19 France: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 20 France: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 21 France: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 22 Germany: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 23 Germany: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 24 Germany: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 25 Italy: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 26 Italy: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 27 Italy: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 28 Spain: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 29 Spain: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 30 Spain: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 31 Netherlands: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 32 Netherlands: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 33 Netherlands: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 34 Russia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 35 Russia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 36 Russia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 37 Rest of Europe: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 38 Rest of Europe: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 39 Rest of Europe: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 40 Asia Pacific: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 41 Asia Pacific: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 42 Asia Pacific: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 43 China: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 44 China: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 45 China: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 46 India: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 47 India: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 48 India: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 49 Malaysia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 50 Malaysia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 51 Malaysia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 52 Japan: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 53 Japan: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 54 Japan: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 55 Indonesia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 56 Indonesia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 57 Indonesia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 58 South Korea: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 59 South Korea: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 60 South Korea: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 61 Australia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 62 Australia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 63 Australia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 64 Rest of Asia Pacific: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 65 Rest of Asia Pacific: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 66 Rest of Asia Pacific: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 67 Middle East & Africa: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 68 Middle East & Africa: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 69 Middle East & Africa: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 70 Saudi Arabia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 71 Saudi Arabia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 72 Saudi Arabia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 73 UAE: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 74 UAE: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 75 UAE: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 76 Israel: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 77 Israel: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 78 Israel: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 79 South Africa: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 80 South Africa: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 81 South Africa: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 82 Rest of Middle East & Africa: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 83 Rest of Middle East & Africa: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 84 Rest of Middle East & Africa: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 85 Latin America: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 86 Latin America: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 87 Latin America: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 88 Mexico: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 89 Mexico: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 90 Mexico: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 91 Brazil: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 92 Brazil: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 93 Brazil: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 94 Argentina: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 95 Argentina: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 96 Argentina: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 97 Rest of Latin America: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 98 Rest of Latin America: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 99 Rest of Latin America: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)

List of Figures:

  • Figure 1. Global Pneumococcal Vaccine Market, 2019-2032 (USD billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Vaccine Type
  • Figure 7. Global Pneumococcal Vaccine Market, by Vaccine Type, 2023 & 2032 (USD billion)
  • Figure 8. Market by Product
  • Figure 9. Global Pneumococcal Vaccine Market, by Product, 2023 & 2032 (USD billion)
  • Figure 10. Market by End User
  • Figure 11. Global Pneumococcal Vaccine Market, by End User, 2023 & 2032 (USD billion)
  • Figure 12. Global Pneumococcal Vaccine Market Assessment, By Geography, 2019-2032 (USD billion)
  • Figure 13. Strategic Analysis - Global Pneumococcal Vaccine Market
目次
Product Code: PM5107

The global pneumococcal vaccine market size is expected to reach USD 14.43 billion by 2032, according to a new study by Polaris Market Research. The report "Pneumococcal Vaccine Market Share, Size, Trends, Industry Analysis Report, By Vaccine Type (Pneumococcal Conjugate Vaccine, and Pneumococcal Polysaccharide Vaccine); By Product Type; By Distribution Channel; By Region; Segment Forecast, 2024-2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The pneumococcal vaccine market is experiencing significant growth driven by increased awareness about pneumococcal infections and the expansion of government-sponsored immunization programs. As public health campaigns highlight the dangers of pneumococcal disease, including pneumonia and meningitis, individuals and healthcare providers are more inclined to seek vaccination. Additionally, governments worldwide are implementing robust immunization initiatives aimed at enhancing community health and reducing healthcare costs associated with pneumococcal diseases. These programs often include subsidies and educational resources, making vaccines more accessible to underserved populations. As awareness continues to rise and vaccination efforts intensify, the demand for pneumococcal vaccines is expected to increase substantially, impacting the pneumococcal vaccine market growth positively.

The pneumococcal vaccine market is driven by government initiatives and health policies that promote widespread vaccination. These programs aim to enhance public health by reducing the incidence of pneumococcal diseases, such as pneumonia and meningitis. As governments implement comprehensive immunization strategies, including funding and awareness campaigns, accessibility to vaccines improves, leading to higher vaccination rates.

Increasing partnerships between biotech firms and market players aimed at developing more effective pneumococcal conjugate vaccines (PCVs) are fueling the pneumococcal vaccine market growth in forecast years. For Instance, in June 2023, SK Bioscience collaborated with Sanofi to create GBP410, a 21-valent PCV that demonstrated positive results in Phase 2 studies involving toddlers and infants. Similarly, in March 2024, Pfizer's PREVENAR 20, a 20-valent PCV, received approval from the European Commission to immunize infants, children, and adolescents across Europe and globally. These strategic alliances enhance research capabilities, expedite development timelines, and expand vaccine access, ultimately driving market growth during projected years.

Pneumococcal Vaccine Market Report Highlights

The pneumococcal polysaccharide vaccine (PPV) segment accounted for the largest market share in 2023 primarily due to global acceptance and easy availability.

The Pneumococcal conjugate vaccine (PCV) segment is expected to witness the highest growth over the study period, as PCV covers more range of the streptococcus pneumoniae.

The Prevnar 13 segment accounted for the largest market share in 2023, as it caters to a wider range of age, and is more efficient in treating the disease.

The Asia Pacific is projected to register the fastest growth over the study period, attributable to the increasing investment in pneumococcal vaccine development.

The global players are GSK plc, Pfizer Inc, Merck, Serum Institute, CSL Ltd., and Sanofi.

Polaris Market Research has segmented the pneumococcal vaccine market report based on vaccine type, product type, distribution channel, and region:

By Vaccine Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Pneumococcal conjugate vaccine (PCV)
  • Pneumococcal polysaccharide vaccine (PPV)

By Product Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Prevnar 13
  • Synflorix
  • Pneumovax23

By Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

  • Distribution partner companies
  • Non-governmental Organizations
  • Government Authorities

By Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Vaccine Types
    • 3.2.1. Primary Vaccine Types
    • 3.2.2. Secondary Vaccine Types

4. Global Pneumococcal Vaccine Market Insights

  • 4.1. Pneumococcal Vaccine Market - Market Snapshot
  • 4.2. Pneumococcal Vaccine Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Incidence of Pneumococcal Disease Across All Age Groups is Driving Market Growth
      • 4.2.1.2. Health Policies Promoting Widespread Vaccination is Propelling Market Size
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Regulatory Hurdles
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Pneumococcal Vaccine Market Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Pneumococcal Vaccine Market, by Vaccine Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • 5.3. Pneumococcal conjugate vaccine
    • 5.3.1. Global Pneumococcal Vaccine Market, by Pneumococcal conjugate vaccine, by Region, 2019-2032 (USD billion)
  • 5.4. Pneumococcal polysaccharide vaccine
    • 5.4.1. Global Pneumococcal Vaccine Market, by Pneumococcal polysaccharide vaccine, by Region, 2019-2032 (USD billion)

6. Global Pneumococcal Vaccine Market, by Product

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • 6.3. Prevnar 13
    • 6.3.1. Global Pneumococcal Vaccine Market, by Prevnar 13, by Region, 2019-2032 (USD billion)
  • 6.4. Synflorix
    • 6.4.1. Global Pneumococcal Vaccine Market, by Synflorix, by Region, 2019-2032 (USD billion)
  • 6.5. Pneumovax23
    • 6.5.1. Global Pneumococcal Vaccine Market, by Pneumovax23, by Region, 2019-2032 (USD billion)
  • 6.6. Other Product
    • 6.6.1. Global Pneumococcal Vaccine Market, by Other Product, by Region, 2019-2032 (USD billion)

7. Global Pneumococcal Vaccine Market, by End User

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • 7.3. Public Sector
    • 7.3.1. Global Pneumococcal Vaccine Market, by Public Sector, by Region, 2019-2032 (USD billion)
  • 7.4. Private Sector
    • 7.4.1. Global Pneumococcal Vaccine Market, by Private Sector, by Region, 2019-2032 (USD billion)

8. Global Pneumococcal Vaccine Market, by Geography

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Pneumococcal Vaccine Market Assessment, By Geography, 2019-2032 (USD billion)
  • 8.3. Pneumococcal Vaccine Market - North America
    • 8.3.1. North America: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
    • 8.3.2. North America: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
    • 8.3.3. North America: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.3.4. Pneumococcal Vaccine Market - U.S.
      • 8.3.4.1. U.S.: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.3.4.2. U.S.: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.3.4.3. U.S.: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.3.5. Pneumococcal Vaccine Market - Canada
      • 8.3.5.1. Canada: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.3.5.2. Canada: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.3.5.3. Canada: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • 8.4. Pneumococcal Vaccine Market - Europe
    • 8.4.1. Europe: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
    • 8.4.2. Europe: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
    • 8.4.3. Europe: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.4.4. Pneumococcal Vaccine Market - UK
      • 8.4.4.1. UK: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.4.4.2. UK: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.4.4.3. UK: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.4.5. Pneumococcal Vaccine Market - France
      • 8.4.5.1. France: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.4.5.2. France: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.4.5.3. France: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.4.6. Pneumococcal Vaccine Market - Germany
      • 8.4.6.1. Germany: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.4.6.2. Germany: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.4.6.3. Germany: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.4.7. Pneumococcal Vaccine Market - Italy
      • 8.4.7.1. Italy: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.4.7.2. Italy: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.4.7.3. Italy: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.4.8. Pneumococcal Vaccine Market - Spain
      • 8.4.8.1. Spain: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.4.8.2. Spain: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.4.8.3. Spain: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.4.9. Pneumococcal Vaccine Market - Netherlands
      • 8.4.9.1. Netherlands: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.4.9.2. Netherlands: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.4.9.3. Netherlands: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.4.10. Pneumococcal Vaccine Market - Russia
      • 8.4.10.1. Russia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.4.10.2. Russia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.4.10.3. Russia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.4.11. Pneumococcal Vaccine Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.4.11.2. Rest of Europe: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.4.11.3. Rest of Europe: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • 8.5. Pneumococcal Vaccine Market - Asia Pacific
    • 8.5.1. Asia Pacific: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
    • 8.5.2. Asia Pacific: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
    • 8.5.3. Asia Pacific: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.5.4. Pneumococcal Vaccine Market - China
      • 8.5.4.1. China: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.5.4.2. China: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.5.4.3. China: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.5.5. Pneumococcal Vaccine Market - India
      • 8.5.5.1. India: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.5.5.2. India: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.5.5.3. India: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.5.6. Pneumococcal Vaccine Market - Malaysia
      • 8.5.6.1. Malaysia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.5.6.2. Malaysia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.5.6.3. Malaysia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.5.7. Pneumococcal Vaccine Market - Japan
      • 8.5.7.1. Japan: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.5.7.2. Japan: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.5.7.3. Japan: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.5.8. Pneumococcal Vaccine Market - Indonesia
      • 8.5.8.1. Indonesia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.5.8.2. Indonesia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.5.8.3. Indonesia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.5.9. Pneumococcal Vaccine Market - South Korea
      • 8.5.9.1. South Korea: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.5.9.2. South Korea: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.5.9.3. South Korea: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.5.10. Pneumococcal Vaccine Market - Australia
      • 8.5.10.1. Australia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.5.10.2. Australia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.5.10.3. Australia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.5.11. Pneumococcal Vaccine Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.5.11.2. Rest of Asia Pacific: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.5.11.3. Rest of Asia Pacific: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • 8.6. Pneumococcal Vaccine Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
    • 8.6.2. Middle East & Africa: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
    • 8.6.3. Middle East & Africa: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.6.4. Pneumococcal Vaccine Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.6.4.2. Saudi Arabia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.6.4.3. Saudi Arabia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.6.5. Pneumococcal Vaccine Market - UAE
      • 8.6.5.1. UAE: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.6.5.2. UAE: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.6.5.3. UAE: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.6.6. Pneumococcal Vaccine Market - Israel
      • 8.6.6.1. Israel: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.6.6.2. Israel: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.6.6.3. Israel: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.6.7. Pneumococcal Vaccine Market - South Africa
      • 8.6.7.1. South Africa: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.6.7.2. South Africa: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.6.7.3. South Africa: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.6.8. Pneumococcal Vaccine Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.6.8.2. Rest of Middle East & Africa: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.6.8.3. Rest of Middle East & Africa: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • 8.7. Pneumococcal Vaccine Market - Latin America
    • 8.7.1. Latin America: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
    • 8.7.2. Latin America: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
    • 8.7.3. Latin America: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.7.4. Pneumococcal Vaccine Market - Mexico
      • 8.7.4.1. Mexico: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.7.4.2. Mexico: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.7.4.3. Mexico: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.7.5. Pneumococcal Vaccine Market - Brazil
      • 8.7.5.1. Brazil: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.7.5.2. Brazil: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.7.5.3. Brazil: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.7.6. Pneumococcal Vaccine Market - Argentina
      • 8.7.6.1. Argentina: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.7.6.2. Argentina: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.7.6.3. Argentina: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.7.7. Pneumococcal Vaccine Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.7.7.2. Rest of Latin America: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.7.7.3. Rest of Latin America: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. GSK plc
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Pfizer Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Merck KGaA
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Serum Institute of India Pvt. Ltd.
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. CSL Ltd.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Sanofi S.A
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Walvax Biotechnology Co., Ltd.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Beijing Minhai Biotechnology Co., Ltd
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Johnson & Johnson
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. AstraZeneca
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Novavax
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development